The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of &bgr;-secretase, also known as &bgr;-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.